ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,241.24
-0.16%
Dow Jones
38,852.86
-0.55%
Gold vs US Dollar
2,345.87
-0.57%
Brent Oil
84.585
0.31%
Bitcoin
67,828.89
-0.68%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Adagene Inc (ADAG)

  7. Adagene Inc (ADAG) News

Adagene (ADAG)

Adagene Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ADAG
DateTimeSourceHeadlineSymbolCompany
22/05/202421:45GlobeNewswire Inc.Adagene to Present at Investor Conferences in JuneNASDAQ:ADAGAdagene Inc
29/03/202413:00GlobeNewswire Inc.Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
07/03/202421:01GlobeNewswire Inc.Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardNASDAQ:ADAGAdagene Inc
01/03/202421:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ADAGAdagene Inc
27/02/202413:00GlobeNewswire Inc.Adagene to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:ADAGAdagene Inc
09/02/202411:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
09/02/202411:00GlobeNewswire Inc.Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabNASDAQ:ADAGAdagene Inc
16/01/202422:01GlobeNewswire Inc.Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)NASDAQ:ADAGAdagene Inc
16/01/202422:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
04/01/202410:00GlobeNewswire Inc.Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI SymposiumNASDAQ:ADAGAdagene Inc
03/11/202316:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
03/11/202316:00GlobeNewswire Inc.Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023NASDAQ:ADAGAdagene Inc
12/10/202313:00GlobeNewswire Inc.Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:ADAGAdagene Inc
29/09/202311:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
07/09/202311:00GlobeNewswire Inc.Adagene to Present at Investor and Scientific Conferences in SeptemberNASDAQ:ADAGAdagene Inc
31/08/202312:32GlobeNewswire Inc.Adagene Reports Six Month Financial Results for 2023 and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
31/08/202312:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
07/07/202321:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
04/05/202314:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
04/05/202314:00GlobeNewswire Inc.Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug ConjugateNASDAQ:ADAGAdagene Inc
28/04/202312:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
28/04/202312:03Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ADAGAdagene Inc
28/04/202312:00GlobeNewswire Inc.Adagene Announces Updates to its Board of DirectorsNASDAQ:ADAGAdagene Inc
18/04/202314:27Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
18/04/202314:17GlobeNewswire Inc.Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid TumorsNASDAQ:ADAGAdagene Inc
28/03/202322:07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
28/03/202321:30GlobeNewswire Inc.Adagene Reports Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
14/03/202322:00GlobeNewswire Inc.Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in AprilNASDAQ:ADAGAdagene Inc
06/03/202300:39GlobeNewswire Inc.Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory BoardNASDAQ:ADAGAdagene Inc
09/02/202313:16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ADAGAdagene Inc
 Showing the most relevant articles for your search:NASDAQ:ADAG

Your Recent History

NASDAQ
AMGN
Amgen
TG
UCCP
Westwater Resources
BIT
P1LPN9
BNP Paribas Issuance
NYSE
LTC-AL
LSE
RM85
Citi Fun 24
EU
BOLS
Lucas Bols NV
ASX
CBALOF
BIT
I07017
Intesa Sanpaolo
USOTC
SMNRF
S2 Minerals (PK)
ASX
XQLQAM
Queensland Treasury
EU
ISUSM
ISHARES SUSM INAV
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved